ISO 10993 is the standard framework for biological evaluation of medical devices, and it is frequently misunderstood — either as a list of tests every medical adhesive must pass, or as a regulatory bureaucracy that can be satisfied by generic paperwork. Neither view is accurate. ISO 10993 is a risk-based framework: the tests required for a specific adhesive in a specific device are determined by a systematic assessment of the patient contact nature, duration, and exposure pathway, not by a blanket requirement list. Understanding how to apply that framework to an adhesive bonding decision prevents both over-testing (expensive and time-consuming tests not required for the application) and under-testing (missing required evaluations that block regulatory submissions).
The ISO 10993 Framework: Starting With Contact Assessment
ISO 10993-1 — the governing document of the standard family — establishes the principle that biological evaluation must begin with characterization of the device’s contact with the patient. The three contact categories are surface-contacting (intact skin, mucous membrane, breached or compromised skin), externally communicating (blood path indirect, tissue/bone/dentin contacting, circulating blood contacting), and implant (tissue/bone contacting, blood contacting).
The duration categories are limited contact (under 24 hours), prolonged contact (24 hours to 30 days), and permanent contact (over 30 days).
For each combination of contact nature and duration, ISO 10993-1 recommends a biological evaluation endpoint matrix. The matrix identifies which biological effects should be evaluated — cytotoxicity, sensitization, irritation, systemic toxicity (acute, subacute, subchronic), genotoxicity, hemocompatibility, implantation, carcinogenicity, reproductive and developmental toxicity, and degradation. Not all effects must be tested; the matrix indicates which are recommended for each contact category, and the device biological evaluation plan must justify the approach taken.
For most non-implantable external devices with indirect or no patient contact, the required endpoints are: cytotoxicity (required for all categories), sensitization (required for all external contact categories), and irritation (required for mucous membrane and prolonged skin contact). This is a three-test battery for many common applications — not the full 15-endpoint list that a permanent implant requires.
Cytotoxicity Testing: The Baseline Requirement
ISO 10993-5 cytotoxicity testing is the baseline biological test that applies to essentially every medical device material in patient contact. It evaluates whether the material, or extracts from the material under standardized conditions, reduces the viability or proliferation of mammalian cells in culture.
For epoxy adhesives, cytotoxicity is tested on an extract prepared from the cured adhesive using a standardized vehicle (saline, DMSO, or cell culture medium) at a standardized extraction ratio (typically 6 cm² per mL at 37°C for 24 hours for intact surfaces). The extract is applied to a confluent monolayer of L-929 mouse fibroblast cells (the standard cell line for this test) and cell viability is assessed after 24 hours.
A cytotoxicity result is expressed as a grade from 0 (no cytotoxicity) to 4 (severe cytotoxicity). For device materials, Grade 0 to 2 (no reactivity to mild reactivity) is generally accepted; Grade 3 or 4 indicates extractable cytotoxic components at levels that require reformulation or reprocessing of the material before patient contact use.
Epoxy adhesives can fail cytotoxicity for several reasons: unreacted amine hardener residuals that leach and are cytotoxic, residual accelerators or catalysts, or reactive diluents that did not fully incorporate into the network during cure. Medical-grade formulations are specifically designed to minimize these residuals at the cure schedule used in production.
Sensitization and Irritation: The Contact-Relevant Tests
ISO 10993-10 covers sensitization and irritation testing. Sensitization testing evaluates whether a material can induce an immune-mediated delayed hypersensitivity reaction — a reaction that could occur in an already-sensitized patient on subsequent contact with the device. The standard animal test is the guinea pig maximization test (GPMT) or Buehler test; alternative in vitro and in chemico assays (DPRA, h-CLAT, KeratinoSens) are accepted as alternatives under the ISO 10993-10:2021 update.
For epoxy adhesives, sensitization potential is primarily associated with unreacted epoxy groups and amine hardener residuals. Bisphenol-A diglycidyl ether (BADGE), the standard epoxy resin backbone, is a known sensitizer at certain concentrations; epoxy adhesives with high residual BADGE content in the cured product can elicit sensitization in susceptible individuals. Fully cured, low-residual-BADGE formulations have lower sensitization potential.
Irritation testing under ISO 10993-23 evaluates the potential for local tissue irritation on direct contact. For skin-contact applications, intracutaneous reactivity testing (ISO 10993-10) or direct skin application studies characterize the inflammatory response to material extracts.
For testing data for specific Incure formulations against cytotoxicity, sensitization, and irritation endpoints, Email Us — Incure can provide test reports suitable for device regulatory submissions.
Extractables and Leachables for Fluid-Contact Applications
For adhesives in fluid-contact applications — bonding within fluid pathways, sealing manifolds, assembling flow cells — the extractables and leachables assessment under ISO 10993-12 and ISO 10993-17 is required in addition to the standard biological endpoints.
Extractables testing characterizes what chemical entities can be removed from the cured adhesive under aggressive extraction conditions (simulating worst-case patient exposure). Analytical methods — GC-MS, LC-MS, and ICP-OES for metals — identify and quantify the extractable species. The extraction conditions (solvent polarity, temperature, duration) should be appropriately aggressive to identify potential leachables.
Leachables assessment evaluates what actually transfers to the patient-contacting fluid under use conditions. ISO 10993-17 risk assessment uses toxicological threshold values (permitted daily exposure, or PDE) to determine whether the identified leachable quantities represent a patient safety risk. For extractables well below the analytical evaluation threshold (AET), further risk assessment is not required; for extractables above AET, a compound-specific risk assessment based on available toxicological data must be completed.
Practical Application: What Testing Is Actually Needed
For a device manufacturer evaluating a specific adhesive for a specific application, the biocompatibility evaluation path is:
Define the contact category and duration from ISO 10993-1. Determine the recommended biological endpoint matrix. Review what testing data the adhesive supplier has available. Determine whether gap testing is required for the remaining endpoints. Submit a biological evaluation plan and report documenting the approach.
For most non-implantable devices with surface contact only, a medical-grade epoxy with cytotoxicity, sensitization, and irritation data from the supplier covers the required endpoints. The device manufacturer documents the rationale in the biological evaluation report, references the supplier test data, and confirms that the device use conditions fall within the test conditions used.
Contact Our Team to discuss the ISO 10993 test data available for Incure medical-grade epoxy formulations and the documentation package for your device regulatory submission.
Visit www.incurelab.com for more information.